Researchers’ study show advancements in GP38 contributions to CCHFV and monoclonal antibody therapies
U.S. Army Medical Research Institute of Infectious DiseasesA recent study published in Science Translational Medicine involving scientists from the U.S. Army Medical Research Institute of Infectious Diseases in collaboration with scientists from the Albert Einstein College of Medicine and the University of California-Berkeley have advanced discoveries surrounding the viral glycoprotein GP38 expressed by the Crimean-Congo hemorrhagic fever virus (CCHFV).